- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02058381
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer (B-YOND)
March 5, 2020 updated by: Novartis Pharmaceuticals
A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy in hormone receptor-positive MBC, the purpose of this phase Ib trial is to assess the maximum tolerated dose (MTD) and/or the RP2D(s), to characterize the safety and tolerability, to determine the single and multiple dose PK profile and assess the preliminary anti-tumor activity of alpelisib and buparlisib in combination with tamoxifen plus goserelin acetate in premenopausal hormone receptor-positive advanced breast cancer patientsgroup.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- Novartis Investigative Site
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Novartis Investigative Site
-
-
Korea
-
Gyeonggi-do, Korea, Korea, Republic of, 10408
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 05505
- Novartis Investigative Site
-
Seoul, Korea, Korea, Republic of, 06351
- Novartis Investigative Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Novartis Investigative Site
-
Taichung, Taiwan, 407
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
Taipei, Taiwan, 112
- Novartis Investigative Site
-
Taipei, Taiwan, 10449
- Novartis Investigative Site
-
-
TWN
-
New Taipei City, TWN, Taiwan, 23561
- Novartis Investigative Site
-
-
Taoyuan/ Taiwan ROC
-
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patient has histologically and/or cytologically confirmed diagnosis of breast cancer
- Patient has radiological or objective evidence of inoperable locally advanced or metastatic breast cancer
- Patient has HER2-negative breast cancer (based on most recently analyzed tumor sample)
- Patient has ER positive and/or PgR positive breast cancer by local laboratory testing
Patient is premenopausal. Premenopausal status is defined as either:
- patient had last menstrual period within the last 12 months, OR
- if on tamoxifen within the past 3 months, with a plasma estradiol ≥10 pg/mL and FSH ≤40 IU/l or in the premenopausal range, according to local laboratory definition , OR
- in case of chemotherapy induced amenorrhea, with a plasma estradiol ≥10 pg/mL) and/or FSH ≤40 IU/l or in the premenopausal range according to local laboratory definition.
- Patient has no previous history of endocrine therapy in the metastatic setting.
Note:
- Patients who received oral endocrine therapy with duration less than 3 weeks or ≤1 injection of LHRH agonist and discontinued for a reason other than suspicious or evidence of disease progression are eligible
- Adjuvant treatment with tamoxifen monotherapy and LHRH analogue monotherapy is allowed. Patients who received tamoxifen plus LH-RH agonist/antagonist in the adjuvant setting are eligible provided they start investigational treatment at least 12 months after the last dose of tamoxifen or LH-RH agonist/antagonist, whichever came later.
Patients who were already established on bisphosphonate therapy may continue on bisphosphonates.
- Patient has received ≤1 prior chemotherapy line for MBC
- For patient who received prior systemic therapy, radiological or objective evidence of recurrence or progression on or after the last systemic therapy is needed
- Patient must have as per RECIST 1.1:
- measurable disease or
non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.
- Patient has adequate bone marrow and organ function as defined by the following laboratory values:
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≦ 2 which the investigator believes is stable at the time of screening.
- Patient has negative serum pregnancy test (β-hCG) within 72 hrs before starting study treatment.
Exclusion criteria
- Patient is post-menopausal.
- Patient has received previous endocrine treatments in the metastatic setting.
- Patient has received previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitors
- Patient has received more than one chemotherapy line for metastatic disease
- Patient has symptomatic CNS metastases
- Patient who has received wide field radiotherapy ≦ 4 weeks or limited field radiation for palliation ≦ 2 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy (with exception of alopecia alopecia)
- Patient has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy
- Patient is currently receiving increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (> 5 days) can induce CYP3A4
- Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed
- Patient is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP3A. The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment phase is initiated.
- Patient has a score ≧ 12 on the PHQ-9 questionnaire
- Patient selects a response of "1, 2 or 3" to question number 9 on the PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation (independent of the total score of the PHQ-9)
- Patient has a GAD-7 mood scale score ≧ 15
- Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others) or patients with active severe personality disorders (defined according to DSM- IV) are not eligible.
- Patient has ≧ Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety
- Patient has active cardiac disease or a history of cardiac dysfunction
- Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
Patient has any of the following cardiac conduction abnormalities
- Ventricular arrhythmias except for benign premature ventricular contractions
- Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication
- Conduction abnormality requiring a pacemaker
- Other cardiac arrhythmia not controlled with medication
- Patient has a QTcF > 480 msec on the screening ECG (using the QTcF formula)
- Patient is currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to treatment start.
- Patient has chronic pulmonary disease including dyspnea at rest from any cause or with interstitial lung disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (alpelisib)
Alpelisib plus Tamoxifen and Goserelin (Group 1)
|
BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
|
Experimental: Group 2 (buparlisib)
Buparlisib plus Tamoxifen and Goserelin (Group 2)
|
BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D)
Time Frame: 12 months
|
To estimate the MTD(s) and/or the RP2D(s) of a) alpelisib in combination with tamoxifen plus goserelin acetate (Group 1) and b) buparlisib in combination with Tamoxifen plus goserelin acetate (Group 2) in premenopausal hormone receptor-positive locally advanced or MBC patients.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence, type, intensity, severity and seriousness of Adverse Events (AEs) during the first 2 cycles dose interruptions, reductions and dose intensity during the study
Time Frame: 12 months
|
To characterize the safety and tolerability of a) alpelisib in combination with tamoxifen plus goserelin acetate and b) buparlisib in combination with Tamoxifen plus goserelin acetate
|
12 months
|
Alpelisib/buparlisib: plasma concentrations and PK parameters, including but not limited to AUC0-t, AUC0-inf, AUC0-24, Cmax, tmax, CL/F, half-life t1/2 and other PK parameters if deemed appropriate. Tamoxifen: trough plasma concentrations
Time Frame: 12 months
|
To determine the single and multiple dose PK profile of a) alpelisib in combination with tamoxifen plus goserelin acetate and b) buparlisib in combination with Tamoxifen plus goserelin acetate
|
12 months
|
Preliminary anti-tumor activity acccording to RECIST 1.1 : It will include overall response rate, clinical benefit, progression free survival and proportion of patients who are alive without progression at 9 months from the date of treatment start
Time Frame: 12 months
|
To assess the preliminary anti-tumor activity of a) alpelisib in combination with tamoxifen plus goserelin acetate and b) buparlisib in combination with Tamoxifen plus goserelin acetate
|
12 months
|
Index score from the EQ-5D-5L; and WPAI-GH scores for work time missed, impairment while working, overall work impairment, and activity impairment
Time Frame: 12 months
|
To evaluate and compare the impact of alpelisib and buparlisib in combination with tamoxifen plus goserelin on patient-reported health status and impact on work using the EQ-5D-5L and WPAI-GH questionnaires.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2014
Primary Completion (Actual)
June 19, 2018
Study Completion (Actual)
June 19, 2018
Study Registration Dates
First Submitted
January 16, 2014
First Submitted That Met QC Criteria
February 6, 2014
First Posted (Estimate)
February 10, 2014
Study Record Updates
Last Update Posted (Actual)
March 9, 2020
Last Update Submitted That Met QC Criteria
March 5, 2020
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBYL719XIC01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre-menopausal Breast Cancer
-
Novartis PharmaceuticalsCompletedPost Menopausal Breast CancerTaiwan, Malaysia, Turkey, Australia, Korea, Republic of, Thailand, Jordan, India, Vietnam, Morocco, Tunisia, Indonesia, South Africa
-
University of MessinaCompletedPre-menopausal Irregular Cycles and BleedingsItaly
-
University of Wisconsin, MadisonMillennium Pharmaceuticals, Inc.CompletedPost Menopausal, Hormone Receptor Positive Breast CancerUnited States
-
AstraZenecaCompletedBreast Cancer | Post MenopausalItaly
-
British Columbia Cancer AgencyJanssen Research & Development, LLCWithdrawnPost-menopausal ER+ Stage I-IIIA Primary Operable Breast CancerCanada
-
PfizerCompletedPost Menopausal Women With Early Breast Cancer
-
Regional Oncologic CenterEuropean Organisation for Research and Treatment of Cancer - EORTC; Scandinavian... and other collaboratorsCompletedBreast Cancer | Menopausal SymptomsFinland, Norway, Poland, Sweden, Switzerland
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Hot Flashes | Menopausal SymptomsUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and... and other collaboratorsCompletedBreast Cancer | Infertility | Menopausal SymptomsItaly, Australia, Switzerland, Belgium, Hungary, New Zealand
-
PrECOG, LLC.NovartisCompletedMetastatic Breast CancerUnited States
Clinical Trials on alpelisib (BYL719)
-
Novartis PharmaceuticalsAvailablePIK3CA-Related Overgrowth Spectrum (PROS)
-
Lawson Health Research InstituteActive, not recruitingHead and Neck Squamous Cell CancerCanada
-
Novartis PharmaceuticalsActive, not recruitingPIK3CA-related Overgrowth Spectrum (PROS)Spain, France, Ireland, United States
-
New Mexico Cancer Care AllianceNo longer available
-
Novartis PharmaceuticalsRecruitingLymphatic MalformationsSpain, France, Germany, Australia, United States
-
Novartis PharmaceuticalsAvailableHR+, HER2-, Advanced Breast Cancer
-
Novartis PharmaceuticalsCompletedBreast CancerCanada, Italy, Czechia, United States, Belgium, Austria, Germany, Spain, Japan, Lebanon, Australia, Bulgaria, Israel, Netherlands, Colombia, Hong Kong, Brazil
-
Centre Hospitalier Universitaire DijonNovartis PharmaceuticalsRecruitingMegalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)France
-
Novartis PharmaceuticalsNantCell, Inc.TerminatedPIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid TumorsSpain, Belgium, United States, Canada
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; Peter MacCallum Cancer Centre, AustraliaNot yet recruitingArteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditionsAustralia